Blood Clots in Patients with PNH, with Dr. Maxim Norkin
Dr. Norkin explains why and how patients with PNH can develop blood clots, as well as prevention and treatment.
AAMDSIF is proud to announce the launch of our new website! You'll now find everything quickly and easily.
Our patients, families, and caregivers have been asking us for more ways to learn about rare blood cancers and bone marrow failure diseases. So, we're coming to you today, thanks to generous support from individual donors and our corporate partners.
Dr. Norkin explains why and how patients with PNH can develop blood clots, as well as prevention and treatment.
Dr. Timothy Pardee discusses treatments for AML, or Acute Myeloid Leukemia, occurring in older adults.
Dr. Allyson Pishko shares the latest advances in the treatment of PNH, or Paroxysmal Nocturnal Hemoglobinuria.
Dr. Nandita Khera discusses why and when transplants can be recommended for older patients in this podcast episode.
Dr. Rory Shallis discusses a variety of current treatments for MDS, or Myelodysplastic Syndromes
Dr. Jacqueline Garcia discusses the use of hypomenthylating agents.
The recently-approved hypomethylating treatment, Inoqvi, is a daily oral version of two IV or subcutaneous medications. Listen to Dr. Amer Zeidan of Yale Cancer Center explain which MDS patients could qualify, and what it means for their treatment at the link.
Dr. Eunice Wang explains the origin and treatment of secondary MDS. Dr. Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Center.
Dr. David Steensma discusses MDS and toxins with Leigh Clark, Patient Educator. Dr. Steensma is an associate professor at Harvard Medical School and faculty member in the leukemia program at the Dana-Farber Cancer Institute and Brigham and Women's Hospital in Boston, Massachusetts and the Edward P. Evans Chair in MDS at Dana-Farber Cancer Institute
Dr. Abdulraheem Yacoub talks with Leigh Clark about MDS-MPN overlap. He includes how molecular testing is used in determining treatment options.
He also discusses the newly approved drug, Luspatercept, for the treatment of MDS and MDS-MPN overlap syndromes.
Special thanks to Abbvie and Taiho Oncology